GLP-1 Drugs and Gallbladder Risk: What Trials Show

GLP-1 Safety and Side Effects

37% higher risk

A meta-analysis of 76 randomized clinical trials found GLP-1 receptor agonists increased the risk of gallbladder or biliary diseases by 37% compared to controls.

He et al., JAMA Internal Medicine, 2022

He et al., JAMA Internal Medicine, 2022

View as image

Every class of weight loss medication that has been studied long enough has revealed gallbladder complications. GLP-1 receptor agonists are no exception. He et al. (2022) published the definitive meta-analysis in JAMA Internal Medicine: across 76 randomized clinical trials with 103,371 participants, GLP-1 receptor agonists increased the risk of gallbladder or biliary diseases by 37% (RR 1.37, 95% CI 1.23-1.52).^[1] The risk was higher for cholelithiasis (gallstones, RR 1.27), cholecystitis (gallbladder inflammation, RR 1.36), and biliary disease overall. The effect was dose-dependent, duration-dependent, and substantially larger in weight loss trials than in diabetes trials. This is a real safety signal, confirmed across multiple data sources, with a plausible biological mechanism. For the broader side effect landscape, see our overview on GLP-1 drug interactions, and for a related gastrointestinal concern, see GLP-1 agonists and pancreatitis.

The He meta-analysis: quantifying the signal

The 2022 JAMA Internal Medicine meta-analysis by He et al. is the most comprehensive assessment of GLP-1 gallbladder risk to date.^[1] It included 76 randomized controlled trials with follow-up ranging from 12 weeks to 5.4 years. The analysis found:

Overall risk: GLP-1 receptor agonists increased gallbladder or biliary diseases by 37% (RR 1.37, 95% CI 1.23-1.52).

By specific condition:

• Cholelithiasis (gallstones): RR 1.27, 95% CI 1.10-1.47
• Cholecystitis (gallbladder inflammation): RR 1.36, 95% CI 1.14-1.62
• Biliary disease composite: RR 1.37

By dose: Higher doses carried greater risk (RR 1.56, 95% CI 1.36-1.78) compared to lower doses.

By duration: Longer treatment duration increased risk (RR 1.40, 95% CI 1.26-1.56) versus shorter duration.

By indication: The most striking finding was the difference between weight loss and diabetes indications. In weight loss trials (13 studies), gallbladder risk more than doubled (RR 2.29, 95% CI 1.64-3.18). In diabetes/other trials, the risk increase was 27% (RR 1.27, 95% CI 1.14-1.43). This difference likely reflects greater and more rapid weight loss in obesity trials, with weight loss itself being a known gallstone risk factor.

Why GLP-1 drugs affect the gallbladder

Three interconnected mechanisms explain how GLP-1 receptor agonists promote gallstone formation and gallbladder inflammation.^[2][3]

Cholecystokinin suppression

Cholecystokinin (CCK) is the primary hormone that triggers gallbladder contraction after a meal, squeezing bile into the duodenum to aid fat digestion. Rehfeld et al. (2018) demonstrated that GLP-1 suppresses postprandial CCK secretion.^[3] When CCK release is reduced, the gallbladder does not contract adequately. Bile sits stagnant, concentrates, and becomes supersaturated with cholesterol. This creates the chemical conditions for gallstone crystallization.

This is not a theoretical mechanism. It is the same pathophysiology seen with any intervention that reduces gallbladder motility: prolonged fasting, total parenteral nutrition, vagotomy, and octreotide (another peptide that suppresses CCK). The difference with GLP-1 agonists is that CCK suppression occurs with every dose for as long as the drug is taken.

Bile acid signaling disruption

Ramirez-Mejia et al. (2025) detailed how GLP-1 receptor agonists disrupt farnesoid X receptor (FXR) signaling by reducing FGF19 production.^[2] FXR is a nuclear receptor that regulates bile acid synthesis and transport. When FXR signaling is disrupted, bile acid composition shifts. The resulting bile has an altered ratio of cholesterol to bile salts, favoring cholesterol precipitation and stone formation.

Additionally, bile acids act on two receptors in the gallbladder wall (TGR5 and FXR) that modulate gallbladder relaxation. Altered bile acid composition can change gallbladder smooth muscle tone, further reducing contractility.

Rapid weight loss effect

Rapid weight loss from any cause increases gallstone risk. When the body mobilizes fat stores quickly, the liver secretes more cholesterol into bile. If caloric intake is simultaneously reduced, CCK stimulation from meals decreases, and the gallbladder empties less frequently. The combination of increased biliary cholesterol and decreased gallbladder emptying is the classic recipe for gallstone formation.

This mechanism explains why the He meta-analysis found a 2.29-fold risk in weight loss trials (where patients lost 10-20% body weight) compared to 1.27-fold in diabetes trials (where weight loss was typically 3-7%). The dose-response relationship also fits: higher GLP-1 doses produce more weight loss and more CCK suppression.

Pharmacovigilance: what FAERS reports show

He et al. (2025) analyzed the FDA Adverse Event Reporting System (FAERS) for biliary adverse events associated with GLP-1 receptor agonists and DPP-4 inhibitors.^[4] Among 2,215 biliary adverse event reports involving incretin-based therapies:

• Semaglutide: Reporting odds ratio (ROR) 4.06 (95% CI 3.76-4.39) for biliary disorders
• Liraglutide: ROR 3.88 (95% CI 3.50-4.29)
• DPP-4 inhibitors overall: ROR 3.09 (95% CI 2.83-3.37)

Semaglutide's higher signal may reflect its widespread use and higher doses rather than a genuinely higher per-patient risk compared to liraglutide. FAERS data is subject to reporting bias: newer, more widely prescribed drugs accumulate more adverse event reports regardless of actual risk.

Liang et al. (2024) independently analyzed FAERS data and found that among 68,351 incretin therapy case reports, 1,327 (1.94%) involved hepatobiliary adverse events, with a pooled reporting odds ratio of 2.85.^[5] DPP-4 inhibitors showed significant associations with cholelithiasis and chronic cholecystitis, while GLP-1 agonists showed stronger signals for acute cholecystitis.

The FAERS data consistently shows a signal, but pharmacovigilance databases cannot establish causation or determine absolute risk. They detect disproportionate reporting, which may reflect both true risk increases and prescriber/patient awareness effects.

Agent-by-agent breakdown

Semaglutide

Semaglutide has the most biliary event data because of its widespread use. In STEP trials (obesity indication), gallbladder-related adverse events occurred in approximately 2.6% of semaglutide-treated patients versus 1.2% on placebo. In SUSTAIN and PIONEER trials (diabetes indication), rates were lower, consistent with the dose and weight loss differential.

Liraglutide

The LEADER trial reported cholelithiasis in 1.0% of liraglutide patients versus 0.8% on placebo. The SCALE trials (obesity) showed higher rates: approximately 2.5% versus 1.1% on placebo. Frazier and Hasler (2025) noted that liraglutide at the 3.0 mg obesity dose carries higher gallbladder risk than the 1.8 mg diabetes dose, consistent with the dose-response pattern.^[6]

Tirzepatide

Gong et al. (2025) published a meta-analysis specifically examining tirzepatide and biliary disease risk across randomized controlled trials in type 2 diabetes and obesity.^[7] The analysis found no statistically significant increase in biliary disease with tirzepatide versus placebo, though confidence intervals were wide. Given tirzepatide's shorter time on market and the fewer total patient-years of data compared to semaglutide and liraglutide, this should be interpreted cautiously. The SURPASS and SURMOUNT programs showed gallbladder event rates of approximately 0.6-1.5%, lower than semaglutide trials but potentially reflecting different patient populations and follow-up durations.

Dulaglutide and exenatide

The REWIND trial (dulaglutide) and EXSCEL trial (exenatide) both reported low absolute rates of gallbladder events with no clear excess over placebo. These agents produce less weight loss than semaglutide or tirzepatide at typical doses, which may partly explain the lower signal.

Real-world context: how large is the absolute risk?

Robles et al. (2025) conducted a population-based study comparing GLP-1 receptor agonist users with SGLT-2 inhibitor users in Spain.^[8] The study found no statistically significant increase in biliary disease with GLP-1 agonists versus SGLT-2 inhibitors (HR 1.12, 95% CI 0.76-1.65). This suggests that in typical clinical practice, where patients are monitored and dosing is gradual, the absolute risk increase may be modest.

The relative risk of 37% from the He meta-analysis, while statistically robust, must be placed in the context of the baseline rate. In the general population, symptomatic gallstone disease affects approximately 1-2% of adults per year. A 37% relative increase raises this to roughly 1.4-2.7% per year. For most patients, this is a manageable risk, particularly when weighed against the cardiovascular, metabolic, and renal benefits of GLP-1 therapy.

The risk calculus shifts for patients with pre-existing gallbladder disease, prior cholecystectomy (which eliminates the risk entirely), or known gallstones. The Abdulraheem et al. (2025) case report highlighted that acute cholecystitis can occur even in settings where clinicians are not expecting it, such as after routine colonoscopy in a patient on GLP-1 therapy.^[9]

The weight loss confounder

Disentangling the GLP-1 receptor agonist effect from the weight loss effect is difficult. Bariatric surgery, very low calorie diets, and orlistat all increase gallstone risk through rapid weight loss. The 2.29-fold risk in GLP-1 weight loss trials mirrors the gallstone risk seen after Roux-en-Y gastric bypass (15-22% incidence of new gallstones within the first postoperative year).

Kazi et al. (2025) reviewed this question and noted that some evidence suggests GLP-1/GIP dual agonists may have a partially protective effect on gallbladder function through GIP receptor-mediated pathways, though the data is limited.^[10] This is an active area of investigation. For now, it remains unclear what proportion of the gallbladder risk is intrinsic to GLP-1 receptor activation versus a consequence of the weight loss it produces. The dose-response relationship and CCK suppression data suggest both factors contribute.

Gallbladder risk versus other GLP-1 gastrointestinal effects

Gallbladder complications occupy a specific niche in the GLP-1 side effect landscape. Unlike nausea on semaglutide or tirzepatide, which affects 20-45% of patients but is transient and rarely treatment-limiting, gallbladder events are uncommon but can require surgical intervention. In the STEP 1 trial, Wilding et al. (2021) reported that gastrointestinal events led to treatment discontinuation in 4.5% of semaglutide patients, but most of these were nausea and diarrhea, not biliary events.^[11]

The distinction matters clinically. Nausea improves with dose titration and time. Gallstones do not resolve spontaneously. Once formed during GLP-1 treatment, gallstones persist regardless of whether treatment continues or stops. This makes gallbladder complications a low-probability but higher-consequence adverse event compared to the common gastrointestinal symptoms that dominate early treatment.

Injection site reactions are another common concern that differs from gallbladder risk in that they are localized, self-limiting, and have no systemic consequences. The gallbladder signal is qualitatively different from all of these: it shares the dose-response relationship and weight-loss dependency of gastrointestinal symptoms but produces a structural change (stone formation) rather than a functional one.

What the evidence does not resolve

Several questions remain unanswered. Whether ursodeoxycholic acid (UDCA) prophylaxis, commonly used after bariatric surgery to prevent gallstones, would reduce gallbladder events during GLP-1 therapy has not been tested in a randomized trial. Stokes et al. (2014) demonstrated UDCA reduced gallstone risk by 67% during rapid weight loss from dieting and bariatric surgery, but this finding has not been extended to pharmacological weight loss with GLP-1 agonists.

Whether slower dose titration reduces gallbladder risk independently of final dose is unknown. The He meta-analysis found higher risk at higher doses, but could not distinguish dose effects from weight loss magnitude effects because the two are correlated.

Long-term gallbladder disease rates beyond 5 years of continuous GLP-1 therapy have not been reported. The STEP 1 extension by Wilding et al. (2022) showed that weight regain occurred after semaglutide withdrawal, but did not specifically track gallbladder outcomes during or after the extension period.^[12]

Whether prior cholecystectomy patients face different gastrointestinal risks on GLP-1 agonists, such as bile reflux or bile salt diarrhea, has received limited study. Patients who have already had their gallbladder removed cannot develop cholelithiasis or cholecystitis, but may still experience biliary complications.

The risk appears to be front-loaded. Most gallbladder events in clinical trials occurred during the first 6-12 months of therapy, when weight loss is most rapid. Whether the risk attenuates once weight stabilizes is suggested by the data but not definitively established. This pattern mirrors bariatric surgery outcomes, where gallstone formation is concentrated in the rapid weight loss phase.

For the broader side effect landscape across all GLP-1 agents, the gastroparesis evidence covers delayed gastric emptying, the retinopathy data and thyroid cancer evidence address other commonly discussed safety signals, and our comprehensive side effects overview provides the full risk landscape across all adverse events reported in clinical trials.

The Bottom Line

GLP-1 receptor agonists carry a 37% increased risk of gallbladder and biliary disease across 76 randomized trials, with the risk more than doubling in weight loss indications. The mechanism involves CCK suppression reducing gallbladder motility, bile acid signaling disruption, and rapid weight loss increasing biliary cholesterol. The absolute risk increase is modest in clinical practice. The signal is real, reproducible, and biologically plausible. It does not change the risk-benefit calculation for most patients but is relevant for clinical monitoring, particularly during the first year of treatment when weight loss is most rapid.

Frequently Asked Questions

Do GLP-1 drugs cause gallbladder problems?

GLP-1 receptor agonists increase the risk of gallstone formation and gallbladder inflammation by approximately 37%, according to a meta-analysis of 76 randomized trials with 103,371 participants (He et al., JAMA Internal Medicine, 2022). The risk is higher at higher doses, with longer treatment, and in patients using GLP-1s for weight loss rather than diabetes.

What are the signs of gallbladder problems on semaglutide?

Gallbladder problems on semaglutide typically present as right upper abdominal pain, particularly after fatty meals. Nausea, vomiting, and pain radiating to the right shoulder blade can indicate gallstone disease or cholecystitis. In STEP obesity trials, approximately 2.6% of semaglutide-treated patients developed gallbladder-related adverse events versus 1.2% on placebo.

Why do GLP-1 drugs cause gallstones?

GLP-1 receptor agonists promote gallstone formation through three mechanisms: suppression of cholecystokinin (CCK), the hormone that triggers gallbladder contraction (Rehfeld et al., 2018); disruption of bile acid signaling through FXR/FGF19 pathways; and rapid weight loss causing increased cholesterol secretion into bile. The combination of reduced gallbladder emptying and cholesterol-supersaturated bile creates conditions for stone crystallization.

Is tirzepatide safer for gallbladder than semaglutide?

A meta-analysis of tirzepatide randomized trials found no statistically significant increase in biliary disease versus placebo (Gong et al., 2025), compared to the 37% increase seen with GLP-1 agonists overall. However, tirzepatide has fewer total patient-years of data, and confidence intervals were wide. Direct head-to-head comparisons of gallbladder safety between tirzepatide and semaglutide have not been conducted.

Should I get my gallbladder checked before starting Ozempic?

Prescribing information does not mandate pre-treatment gallbladder imaging. Patients with known gallstones, prior gallbladder symptoms, or risk factors (female sex, age over 40, obesity, rapid prior weight loss) may warrant baseline ultrasound evaluation. Approximately 2-3% of patients on GLP-1 agonists for weight loss develop gallbladder events in clinical trials.

Does the gallbladder risk go away after stopping GLP-1 drugs?

Once gallstones have formed, they do not dissolve when the drug is stopped. The risk of new stone formation likely decreases after discontinuation as CCK signaling normalizes and weight stabilizes. Most gallbladder events in clinical trials occurred during the first 6-12 months, when weight loss was most rapid. No long-term discontinuation studies have specifically tracked gallbladder outcomes.